Low-dose BCMA/CD3 (CM336) treatment for newly diagnosed AL (light-chain) amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm, single-center phase 2 trial tests low-dose CM336, a BCMA/CD3 bispecific antibody, in adults with newly diagnosed systemic light‑chain (AL) amyloidosis and measurable disease. Participants receive the investigational antibody and are followed for safety, changes in involved free light chains (dFLC), and organ function over the treatment and follow-up periods. Key inclusion requirements include age ≥18, ECOG performance status ≤2, measurable dFLC (≥50 mg/L), and adequate blood counts and organ function. The trial aims to document preliminary hematologic and organ responses and to characterize adverse events to guide further development.

Why it matters

Who can join: the full rules

1. The patient is informed of and voluntarily signs the informed consent form (ICF).
2. Age ≥18 years, regardless of sex.
3. Confirmed diagnosis of primary light-chain (AL) amyloidosis, in accordance with the Guidelines for the Diagnosis and Treatment of Systemic Light-chain Amyloidosis (2021 Revision).
4. Measurable disease at screening, defined as:

   * Difference between involved and uninvolved free light chains (dFLC) ≥50 mg/L, or
   * Serum involved free light chain ≥50 mg/L with an abnormal κ:λ ratio.
5. ECOG performance status ≤2.
6. Adequate organ function within 3 days prior to the first dose of the investigational drug, meeting all of the following criteria:

   i. Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L, with no granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) administration within 7 days, and no pegylated G-CSF administration within 14 days prior to testing; ii. Hemoglobin (Hb) ≥75 g/L, with no whole blood or red blood cell transfusion within 7 days prior to testing; iii. Platelet count ≥70 × 10⁹/L, with no whole blood transfusion, platelet transfusion, or thrombopoietin receptor agonist treatment within 7 days prior to testing; iv. Hepatic function: alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤3 × ULN, total bilirubin ≤2 × ULN (subjects with Gilbert's syndrome are eligible if direct bilirubin ≤2 × ULN); v. Coagulation: international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5 × ULN; vi. Renal function: estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73 m², calculated using the CKD-EPI equation.
7. Male and female patients of childbearing potential, and their partners, must agree to use effective contraceptive methods deemed appropriate by the investigator throughout the treatment period and for at least 3 months thereafter.
8. Male patients must agree not to donate sperm from the screening period until 90 days after the last dose of the investigational drug.
9. The patient must be willing and able to comply with all study procedures and follow-up visits.
10. Women not of childbearing potential are eligible for enrollment. Women of childbearing potential must have a negative serum or urine β-hCG pregnancy test at screening.

Note:

A woman of childbearing potential is defined as a sexually mature woman who has not undergone surgical sterilization (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) and has not been postmenopausal for at least 12 consecutive months for reasons other than medical treatment. Women using oral contraceptives or intrauterine devices are considered of childbearing potential. Male subjects (including those who have undergone vasectomy) must agree to use condoms during sexual intercourse with women of childbearing potential and must have no plans to father a child from the time of signing the ICF until 3 months after the last dose of study treatment.

Where it's running

• Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Gang An, MD
• Email: angang@ihcams.ac.cn
• Phone: 13502181109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TQB2934 injection for systemic light chain amyloidosis

  This trial will test whether a subcutaneous injection of TQB2934 is safe and can improve blood response in adults with relapsed or refractory systemic light chain amyloidosis who have had daratumumab and bortezomib.

  Recruiting Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 26 other locations · NCT07266116

• Testing linvoseltamab for treating relapsed or refractory AL amyloidosis in adults

  This study is testing a new drug called linvoseltamab to see if it can help adults with relapsed or refractory AL amyloidosis feel better and improve their organ function.

  Recruiting at 20 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 20 other locations · NCT06292780

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or refractory AL (light-chain) amyloidosis

  This trial will try AZD0120, a CAR T cell therapy that targets CD19 and BCMA, to see if it is safe and helps people with relapsed or refractory AL (light-chain) amyloidosis.

  Recruiting at 15 sites Phase 1/2 Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 17 other locations · NCT07081646

• HBI0101 CAR-T therapy for multiple myeloma and light-chain amyloidosis

  This study is testing a new CAR-T therapy called HBI0101 to see if it can help people with relapsed or hard-to-treat multiple myeloma and light-chain amyloidosis feel better.

  Recruiting Phase 2 Hadassah Medical Organization · Jerusalem · NCT06971380

• How well minimal residual disease is cleared in AL amyloidosis after first-line Dara-BorCyD

  This study tests whether achieving very good partial or complete marrow responses with Dara-BorCyD and planned stem cell transplant helps AL amyloidosis patients, by looking at minimal residual disease after treatment.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07215494

• Using daratumumab to treat patients with light chain amyloidosis

  This study is testing how well daratumumab works for treating light chain amyloidosis in different groups of patients to find the best way to help them.

  Recruiting Nanjing University School of Medicine · Nanjing, Jiangsu · NCT06376214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.